VTGN
Income statement / Annual
Last year (2024), VistaGen Therapeutics, Inc.'s total revenue was $1.06 M,
a decrease of 568.10% from the previous year.
In 2024, VistaGen Therapeutics, Inc.'s net income was -$29.36 M.
See VistaGen Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
Operating Revenue |
$1.06 M
|
-$227,300.00
|
$1.11 M
|
$1.09 M
|
$0.00
|
$0.00
|
$0.00
|
$1.25 M
|
$0.00
|
$0.00
|
Cost of Revenue |
$568,000.00 |
$509,800.00 |
$815,200.00 |
$0.00 |
$103,100.00 |
$91,200.00 |
$80,700.00 |
$0.00 |
$53,500.00 |
$0.00 |
Gross Profit |
$496,000.00 |
-$737,100.00 |
$293,700.00 |
$1.09 M |
-$103,100.00 |
-$91,200.00 |
-$80,700.00 |
$1.25 M |
-$53,500.00 |
$0.00 |
Gross Profit Ratio |
0.47 |
3.24 |
0.26 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
Research and Development
Expenses |
$20.02 M
|
$44.28 M
|
$35.41 M
|
$12.48 M
|
$13.37 M
|
$17.10 M
|
$7.76 M
|
$5.20 M
|
$3.93 M
|
$2.43 M
|
General & Administrative
Expenses |
$14.06 M
|
$12.76 M
|
$10.45 M
|
$6.55 M
|
$6.60 M
|
$7.43 M
|
$6.44 M
|
$5.87 M
|
$13.92 M
|
$4.25 M
|
Selling & Marketing
Expenses |
$0.00
|
$1.90 M
|
$2.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$14.06 M
|
$14.18 M
|
$13.25 M
|
$6.55 M
|
$6.60 M
|
$7.43 M
|
$6.44 M
|
$5.87 M
|
$13.92 M
|
$4.25 M
|
Other Expenses |
$312,000.00 |
$0.00 |
$0.00 |
$600.00 |
-$827,000.00 |
-$48,700.00 |
-$428,000.00 |
-$427,000.00 |
-$2,300.00 |
-$233,000.00 |
Operating Expenses |
$34.09 M |
$58.45 M |
$48.66 M |
$19.02 M |
$19.97 M |
$24.53 M |
$14.20 M |
$11.07 M |
$17.85 M |
$6.68 M |
Cost And Expenses |
$34.09 M |
$58.96 M |
$48.66 M |
$19.02 M |
$19.97 M |
$24.53 M |
$14.20 M |
$11.07 M |
$17.85 M |
$6.68 M |
Interest Income |
$0.00 |
$49,200.00 |
$20,000.00 |
$15,000.00 |
$45,000.00 |
$8,000.00 |
$0.00 |
$0.00 |
$0.00 |
$5,000.00 |
Interest Expense |
$0.00 |
$23,000.00 |
$232,000.00 |
$13,000.00 |
$15,000.00 |
-$8.00 M |
$8,900.00 |
$5,000.00 |
$777,000.00 |
$4.62 M |
Depreciation &
Amortization |
$568,000.00
|
$509,800.00
|
$815,200.00
|
$117,600.00
|
$103,100.00
|
$91,200.00
|
$80,700.00
|
$54,900.00
|
$53,500.00
|
$59,100.00
|
EBITDA |
-$33.02 M
|
-$58.68 M
|
-$46.82 M
|
-$17.80 M
|
-$20.65 M
|
-$24.44 M
|
-$14.20 M
|
-$10.19 M
|
-$17.80 M
|
-$6.85 M
|
EBITDA Ratio |
-31.03 |
258.16 |
-42.22 |
-16.34 |
0 |
0 |
0 |
-8.15 |
0 |
0 |
Operating Income Ratio
|
-31.03
|
260.41
|
-43.09
|
-16.46
|
0
|
0
|
0
|
-8.2
|
0
|
0
|
Total Other
Income/Expenses Net |
$3.66 M
|
-$51,200.00
|
$19,900.00
|
$2,200.00
|
$30,100.00
|
-$48,700.00
|
-$135,000.00
|
-$427,000.00
|
-$28.59 M
|
-$2.59 M
|
Income Before Tax |
-$29.36 M |
-$59.24 M |
-$47.76 M |
-$17.93 M |
-$20.77 M |
-$24.59 M |
-$14.34 M |
-$10.25 M |
-$47.22 M |
-$13.88 M |
Income Before Tax Ratio
|
-27.59
|
260.63
|
-43.07
|
-16.46
|
0
|
0
|
0
|
-8.2
|
0
|
0
|
Income Tax Expense |
$4,000.00 |
$5,900.00 |
$3,400.00 |
$2,600.00 |
$2,600.00 |
$2,600.00 |
$2,400.00 |
$2,400.00 |
$2,300.00 |
$2,400.00 |
Net Income |
-$29.36 M |
-$59.25 M |
-$47.76 M |
-$17.93 M |
-$20.77 M |
-$24.59 M |
-$14.35 M |
-$10.26 M |
-$47.22 M |
-$13.89 M |
Net Income Ratio |
-27.59 |
260.66 |
-43.07 |
-16.46 |
0 |
0 |
0 |
-8.2 |
0 |
0 |
EPS |
-1.52 |
-8.51 |
-7.24 |
-6.25 |
-14.21 |
-25.83 |
-30.98 |
-40.85 |
-801.28 |
-318.27 |
EPS Diluted |
-1.52 |
-8.51 |
-7.24 |
-6.25 |
-14.21 |
-25.83 |
-30.98 |
-40.85 |
-801.27 |
-315.87 |
Weighted Average Shares
Out |
$19.35 M
|
$6.96 M
|
$6.60 M
|
$2.87 M
|
$1.46 M
|
$952,082.00
|
$463,001.00
|
$251,054.00
|
$58,931.00
|
$43,629.00
|
Weighted Average Shares
Out Diluted |
$19.35 M
|
$6.96 M
|
$6.60 M
|
$2.87 M
|
$1.46 M
|
$952,082.00
|
$463,001.00
|
$251,054.00
|
$58,932.00
|
$43,960.00
|
Link |
|
|
|
|
|
|
|
|
|
|